NCT02293109 - Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 17, 2015

Primary Completion Date

December 13, 2017

Study Completion Date

January 11, 2018

Conditions

Contiguous Stage II Adult Lymphoblastic LymphomaNoncontiguous Stage II Adult Lymphoblastic LymphomaStage I Adult Lymphoblastic LymphomaStage III Adult Lymphoblastic LymphomaStage IV Adult Lymphoblastic LymphomaUntreated Adult Acute Lymphoblastic Leukemia

Interventions

DRUG

carfilzomib

Given IV

DRUG

cyclophosphamide

Given IV

DRUG

vincristine sulfate

Given IV

DRUG

doxorubicin hydrochloride

Given IV

DRUG

dexamethasone

Given PO

DRUG

methotrexate

Given IV

DRUG

cytarabine

Given IV

DRUG

leucovorin calcium

Given IV or PO

DRUG

methylprednisolone

Given IV

BIOLOGICAL

rituximab

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

95817

University of California Davis, Sacramento